Besides, studies also proved the inhibiting effect of many PRRs on tumor progression, e.g., activating TLR8 in tumor cells is capable of preventing the generation of the immunosuppressive metabolite cAMP, thereby reversing immunosuppression in the tumor microenvironment (12); in colorectal cancer, TLR2, NOD1 and NLRP3 in the immune cells facilitate the antitumor activity via triggering the inflammation (13). This evidence concerns the gene TLR2 and neoplasm.